CRVS - Corvus Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue----
Cost of Revenue----
Gross Profit----
Operating Expenses
Research Development38,58646,30529,35611,352
Selling General and Administrative10,63610,2197,6202,418
Non Recurring----
Total Operating Expenses49,22256,52436,97613,770
Operating Income or Loss-49,222-56,524-36,976-13,770
Income from Continuing Operations
Total Other Income/Expenses Net2,283861601-17,565
Earnings Before Interest and Taxes-49,222-56,524-36,976-13,770
Interest Expense----
Income Before Tax-46,939-55,663-36,375-31,335
Income Tax Expense----
Minority Interest----
Net Income From Continuing Ops-46,939-55,663-36,375-31,335
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-46,939-55,663-36,375-31,335
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-46,939-55,663-36,375-31,335